Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 22, 2024 14:15 ET | Source: BioNTech SE

Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine

The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and olderThe KP.2 adaptation is based on FDA...
June 21, 2023 07:00 ET | Source: InflaRx N.V.

InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients

Gohibic is now commercially available for hospitals in the U.S.Gohibic can be used under an Emergency Use Authorization (EUA) granted by the FDA for treatment of certain critically ill COVID-19...
April 04, 2023 14:55 ET | Source: InflaRx N.V.

InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients

Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body's immune responseFDA granted EUA based on Phase III...
January 10, 2023 11:00 ET | Source: Block & Leviton LLP

Veru Inc. Sued By Block & Leviton LLP for Securities Law Violations

BOSTON, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, announces that it has filed a class action lawsuit on behalf of...
December 24, 2022 15:58 ET | Source: The Rosen Law Firm PA

ROSEN, A LEADING LAW FIRM, Encourages Veru, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– VERU

WHY: NEW YORK, Dec. 24, 2022 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Veru, Inc. (NASDAQ: VERU) between May 11, 2022 and...
November 11, 2022 10:26 ET | Source: The Rosen Law Firm PA

ROSEN, A LEADING LAW FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – EIGR

NEW YORK, Nov. 11, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Eiger...
October 12, 2022 10:30 ET | Source: BioNTech SE

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

NEW YORK and MAINZ, GERMANY, OCTOBER 12, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use...
September 26, 2022 06:45 ET | Source: BioNTech SE

Pfizer und BioNTech reichen Antrag auf Notfallzulassung für Auffrischungsimpfung mit einem an Omikron BA.4/BA.5 angepassten bivalenten COVID-19-Impfstoff für Kinder von 5 bis 11 Jahren bei der FDA ein

NEW YORK und MAINZ, Deutschland, 26. September 2022 — Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass sie bei der US-amerikanischen...
September 26, 2022 06:45 ET | Source: BioNTech SE

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

NEW YORK and MAINZ, GERMANY, September 26, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA)...
September 17, 2022 11:00 ET | Source: The Rosen Law Firm PA

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Humanigen, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – HGEN

NEW YORK, Sept. 17, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, 2021 and...

Next Page keyboard_arrow_right